Lorcaserin

Lorcaserin is a weight loss medication that works by activating specific serotonin receptors in the brain to reduce appetite and increase feelings of fullness after eating smaller portions. It was designed to help patients feel satisfied with less food, supporting long-term dietary changes. While no longer available in some markets due to safety concerns identified in post-marketing studies, it remains an important example of how appetite-regulating medications are developed and evaluated.

Lorcaserin (Belviq) is a selective 5-HT2C serotonin receptor agonist that activates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. This stimulates the melanocortin pathway, promoting satiety and reducing food intake. It was FDA-approved in 2012 for chronic weight management but was voluntarily withdrawn in 2020 after the CAMELLIA-TIMI 61 trial showed an increased cancer risk over extended use, highlighting the importance of long-term pharmacovigilance in obesity medicine.

Lorcaserin demonstrates the scientific principle of targeted appetite suppression via serotonin pathways, a concept that continues to inform newer weight loss medications. Understanding its mechanism and withdrawal teaches patients the importance of evidence-based pharmacotherapy and regular medical follow-up during weight management.